AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Apr 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-04-01

Reporting Person: Campbell Bradley L (Director, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-01	Common Stock	M	7500	$6.06	Acquired	363014	Direct
2020-04-01	Common Stock	S	15003	$9.0855	Disposed	348011	Direct
2020-04-01	Common Stock	A	14847	$0.00	Acquired	362858	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-01	Stock Options (right to buy)	$6.06	M	7500	Disposed	2021-06-16	Common Stock (7500)	Direct

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.75 to $9.53 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Granted in the form of Restricted Stock Units for the achievement of the 2018 PRSU Revenue goal. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. The Restricted Stock Units will vest on December 31, 2020, subject to the reporting person's continued service with the Company.

F4: All of the options were fully vested and exercisable as of April 1, 2020.